Tag Archives: Biktarvy

Pfizer’s Xeljanz drops off top June TV spenders list—and Gilead’s Biktarvy fills the void

AbbVie remained the top pharma TV ad spender with Humira in June, and Gilead Sciences continued its TV push for Biktarvy and Truvada. But one long-time list placeholder dropped out of sight: Pfizer’s Xeljanz spent no money on TV ads in June, according to data from real-time TV ad tracker iSpot.tv. That’s unusual for the rheumatoid arthritis and… Read More »